Results 141 to 150 of about 4,256 (179)

Cardiorenal Protective Effects of Renal Denervation in Chronic Kidney Disease

Hypertension Journal, 2020
Sheran Li, Cara M. Hildreth, Jacqueline K. Phillips   +2 more
openaire   +1 more source

Enhancing Heart Health: Expanding the Use of SGLT2 Inhibitors in Cardiovascular Disease

Medicine Advances
Manahil Mubeen, Aasiya Shahbaz Sakarwala, Arif Imdad Bijarani, Muhammad Taha Kamal   +3 more
doaj   +1 more source

Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes.

J Clin Endocrinol Metab
Jack GA, Avenatti E, Kashyap SR, Sadhu AR.   +3 more
europepmc   +1 more source

Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both? [PDF]

Diabetes Obes Metab, 2019
Scholtes RA, van Baar MJB, Lytvyn Y, Bjornstad P, Nieuwdorp M, Cherney DZI, van Raalte DH.   +6 more
europepmc   +1 more source

Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. [PDF]

Diabetes Ther, 2019
Nagahisa T, Saisho Y.
europepmc   +1 more source

Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial. [PDF]

Ann Transl Med, 2017
Borg R, Persson F.
europepmc   +1 more source

Preventing Type 2 Diabetes in At-Risk Cardiorenal Populations. [PDF]

Cureus
de Silva D, Peiris A.
europepmc   +1 more source

Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. [PDF]

Diabetes Obes Metab
Kaur R, Singh A.
europepmc   +1 more source

Cardiorenal therapeutics in a polluted world: interpreting treatment benefit in an environmental context. [PDF]

Am J Prev Cardiol
Meng X, Chen K.
europepmc   +1 more source